The impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, 1997-2010: Evidence from longitudinal, disease-level data

Economics of Innovation and New Technology

Volumn 23, Issue 3, 2014, Pages 239-273

  Lichtenberg, Frank R ^a,b   Pettersson, Billie ^c,d  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

^c Center for Business and Policy Studies (SNS)   (Sweden)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

cost effectiveness; drugs; innovation; longevity; pharmaceutical; Sweden; technology

Indexed keywords

EID: 84897613642     PISSN: 10438599     EISSN: 14768364     Source Type: Journal    
DOI: 10.1080/10438599.2013.828456     Document Type: Article

References (24)

1. Arias, E. 2010. United States Life Tables, 2006. National Vital Statistics Reports, Vol. 58, No. 21, June 28.
2. Australian Productivity Commission. 2005. Impacts of Advances in Medical Technology in Australia, Research Report, Melbourne. Accessed March 7. http://www.pc.gov.au/__data/assets/pdf_file/0003/17193/medicaltechnology.pdf
3. Dorsey, E. R., J. de Roulet, J. P. Thompson, J. I. Reminick, A. Thai, Z. White-Stellato, C. A. Beck, B. P. George, H. Moses III. 2010. "Financial Anatomy of Biomedical Research, 2003 - 2008." JAMA 303 (2): 137-143. Accessed January 13. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3118092/ doi: 10.1001/jama.2009.1987
4. Grossman, G. M., and E. Helpman. 1991. "Quality Ladders in the Theory of Growth." The Review of Economic Studies 58 (1): 43-61. doi: 10.2307/2298044
5. Harper, M. J. 2007. "Technology and the Theory of Vintage Aggregation." In Hard-to-Measure Goods and Services: Essays in Honor of Zvi Griliches, edited by E. R. Berndt and C. R. Hulten, 99-120. Chicago: University of Chicago Press. http://www.nber.org/chapters/c0875
6. Lichtenberg, F. R. 2009a. "The Effect of New Cancer Drug Approvals on the Life Expectancy of American Cancer Patients, 1978-2004." Economics of Innovation and New Technology 18 (5): 407-428. doi: 10.1080/10438590802547142
7. Lichtenberg, F. R. 2009b. "International Differences in Cancer Survival Rates: the Role of New Drug Launches." International Journal of Healthcare Technology and Management 10 (3): 138-155. doi: 10.1504/IJHTM.2009.025818
8. Lichtenberg, F. R. 2010 "Are Increasing 5-Year Survival Rates Evidence of Success Against Cancer? A Reexamination Using Data from the U.S. and Australia." Forum for Health Economics & Policy 13 (2): 1-18 (Health Economics), Article 11. http://www.bepress.com/fhep/13/2/11
9. Lichtenberg, F. R. 2011. "The Quality of Medical Care, Behavioral Risk Factors, and Longevity Growth." International Journal of Health Care Finance and Economics 11 (1): 1-34. doi: 10.1007/s10754-010-9086-y
10. Lichtenberg, F. R. 2012. "The Contribution of Pharmaceutical Innovation to Longevity Growth in Germany and France, 2001-2007." PharmacoEconomics 30 (3): 197-211. doi: 10.2165/11587150-000000000-00000
11. Lichtenberg, F. R. 2013a. "The Effect of Pharmaceutical Innovation on Longevity: Patient Level Evidence from the 1996-2002 Medical Expenditure Panel Survey and Linked Mortality Public-Use Files." Forum for Health Economics and Policy 16 (1): 1-33.
12. Lichtenberg, F. R. 2013b. "The Impact of New (Orphan) Drug Approvals on Premature Mortality from Rare Diseases in the U.S. and France, 1999-2007." European Journal of Health Economics 14 (1): 41-56. doi: 10.1007/s10198-011-0349-4
13. Lichtenberg, F. R. 2013c. "The Impact of Therapeutic Procedure Innovation on Hospital Patient Longevity: Evidence from Western Australia, 2000-2007." Social Science & Medicine 77 (C): 50-59.
14. Lichtenberg, F. R. 2013d. "The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000-2009." Economics and Human Biology, forthcoming. Accessed April 12, 2013. http://www.sciencedirect.com/science/article/pii/S1570677X13000373
15. Lichtenberg, F. R., and G. Duflos. 2008. "Pharmaceutical Innovation and the Longevity of Australians: a First Look." Advances in Health Economics and Health Services Research 19: 95-117. doi: 10.1016/S0731-2199(08)19005-7
16. Murphy, K. M., and R. H. Topel. 2006. "The Value of Health And Longevity." Journal of Political Economy 114 (4 August): 871-904. doi: 10.1086/508033
17. National Science Foundation. 2013. "U.S. Corporate R&D: Volume 1: Top 500 Firms in R&D by Industry Category." Accessed March 7. http://www.nsf.gov/statistics/nsf00301/expendit.htm#intensity
18. Nobelprize.org. 2013. "The Prize in Economics 1987 - Press Release." http://www.nobelprize.org/nobel_prizes/economics/laureates/1987/press.html
19. Nordhaus, W. D. 2003. "The Health of Nations: The Contribution of Improved Health to Living Standards." In Measuring the Gains from Medical Research: An Economic Approach, edited by Kevin Murphy and Robert Topel, 9-40. Chicago: University of Chicago Press.
20. Romer, P. 1990. "Endogenous Technological Change." Journal of Political Economy 98 (5, Part 2): S71-S102. doi: 10.1086/261725
21. Sampat, B. N., and F. R. Lichtenberg. 2011. "What are the Respective Roles of the Public and Private Sectors in Pharmaceutical Innovation?." Health Affairs 30 (2): 332-339. doi: 10.1377/hlthaff.2009.0917
22. Solow, R. M. 1960. "Investment and Technological Progress." In Mathematical Methods in Social Sciences 1959, edited by K. Arrow, S. Karlin and P. Suppes, 89-104. Stanford, CA: Stanford University Press.
23. Squires, D. A. 2011. "The U.S. Health System in Perspective: A Comparison of Twelve Industrialized Nations." Commonwealth Fund pub. 1532 Vol. 16, http://www.commonwealthfund.org/ /media/Files/Publications/Issue%20Brief/2011/Jul/1532_Squires_US_hlt_sys_comparison_12_nations_intl_brief_v2.pdf
24. Tseng, V., F. Yu, F. Lum, and A. Coleman. 2012. "Risk of Fractures Following Cataract Surgery in Medicare Beneficiaries." JAMA 308 (5): 493-501. doi: 10.1001/jama.2012.9014